Hellenic Journal of Cardiology · 2020 · 16 citations · 41 references
MedicineCardiologySurgeryCardiothoracic SurgeryInterventional CardiologyVascular SurgeryAortic StenosisCardiac Valve SurgeryTranscatheter Aortic Valve ReplacementTranscatheter Valve TherapyAortic Valve Disease PrognosisCardiac PacemakersCardiovascular SurgeryCatheter-based Valve InterventionCox Regression
OBJECTIVE: TAVI is more frequently used to treat aortic stenosis with the mandate to have a low as possible rate of adverse events. We present our 30-day outcomes and one-year mortality and examine the factors associated with them. METHODS: A prospective evaluation was performed of all patients who underwent transfemoral TAVI in Nicosia General Hospital from January 2015 until March 2020. MACE were defined as cardiac death, disabling stroke, and/or major vascular complications (VC). Multiple logistic and Cox regression analyses were used to identify the factors associated with 30-day MACE and one-year mortality, respectively. RESULTS: A total of 235 TAVI procedures were performed (178 balloon-expandable, 57 self-expandable). Thirty-day outcomes were MACE: 4.3%, cardiovascular death: 2.1%, disabling stroke: 1.3%, major VC: 1.7%, and contrast induced nephropathy (CIN): 4.3%. There was a rate of 6.2% new pacemaker implantations and 0.9% of more than mild aortic valve regurgitation (AR) at 30 days. Mortality at one year was 15.1%. The balloon-expandable valves appear to have less new pacemakers, less mild AR, lower contrast volume used, and less days of hospitalization, while the self-expandable valves have lower post-procedural gradients. Low hemoglobulin, history of atrial fibrillation (AF), and lower BMI were predictors of 30-day MACE. Serum creatinine >2 mg/dL, history of AF, RVSP >60 mmHg and major VC are predictors of one-year mortality. CONCLUSION: We have shown excellent 30-day results with low incidence of adverse events for both the balloon-expandable and self-expandable valves. Clinical factors are the main predictors of both 30-day MACE and one-year mortality; major VC is a strong predictor of one-year mortality.
41
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith, Martin B. Leon, Michael J. Mack et al. · New England Journal of Medicine · 2011 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +13
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax et al. · European Heart Journal · 2017 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +14
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Martin B. Leon, Craig R. Smith, Michael J. Mack et al. · New England Journal of Medicine · 2016 · 5K citations · Full text
Medicine, Cardiology, Surgery +13